Endocrine Abstracts

Introduction: In a prospective study we determined factors affecting GO activity and poor response to glucocorticoid therapy in patients treated with radioiodine (131-I group) or with anti-thyroid drugs (ATD group).Material and methods: The ATD and 131-I groups consisted of 168 patients (mean age 52.2±11.2 years) and of 46 patients (mean age 52.1±13.3 years), respectively. SoluMedrol pulses (8.0 g) were applied, followed by orbital irradiation ...

Pituitary adenomas represent more than 80% of all sella turcica tumors and 10–15% of all intracranial tumors in adults. Topoisomerase II α (TopoIIα) is recognized as a reliable tumor proliferative activity marker. Evaluation of its expression facilitates the identification of more aggressive neoplasms.Aim: To assess the topoIIα expression in pituitary adenomas as the marker of the tumor aggressiveness, recurrence and progression.<...

In many neoplasms, excessive angiogenesis is prognostic factor, independent from proliferation. Previous studies confirmed correlation between cyclooxygenase-2 (COX-2) expression and micro-vascularization density in pituitary tumors. Moreover, nonsteroidal anti-inflammatory drugs have strong inhibiting effect on COX-2 expression and possible anti-tumor activity.Aim: To assess COX-2 expression in pituitary adenomas, its relation to adenoma type as well as...

Introduction: During clinical observation the behaviour of pituitary tumours is frequently unpredictable. The work was aimed at evaluating Ki-67 and topoisomerase II alpha indices as markers of tumour invasiveness and prognostic factors for postoperative course of disease.Material and methods: The Ki-67 and topoisomerase IIα (Topo IIα) indices were determined by immunochemistry in specimens excised from neurosurgically removed pituitary tumours...